Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-4280A vs physician's choice chemotherapy in relapsed/refractory classical Hodgkin lymphoma post–PD-1
CTR20223041Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of favezelimab + pembrolizumab in classical Hodgkin lymphoma (cHL), sponsored by Merck & Co.. Started Nov 2022; status: terminated.
02
Drugs
favezelimab + pembrolizumab
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on CTR20223041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223041.